Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 10;11(2):00665-2024.
doi: 10.1183/23120541.00665-2024. eCollection 2025 Mar.

Systemic pro-inflammatory response following bronchoscopic lung volume reduction using endobronchial valves

Jorine E Hartman  1   2 , Marieke C van der Molen  1   2 , Marnix R Jonker  2   3 , Rein Posthuma  4   5   6 , Lowie E G W Vanfleteren  7   8 , Dirk-Jan Slebos  1   2 , Simon D Pouwels  1   2   3
Affiliations

Systemic pro-inflammatory response following bronchoscopic lung volume reduction using endobronchial valves

Jorine E Hartman et al. ERJ Open Res. .

Abstract

Rationale: Bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) is an effective treatment for severe COPD patients by improving lung function and quality of life. However, little is known about its effects on systemic inflammation. Therefore, the aim of our study was to investigate whether EBV treatment impacts the inflammatory cytokine profile.

Methods: This study was a predefined sub-study of the SoLVE trial (NCT03474471) that investigated the combination of EBV treatment with pulmonary rehabilitation (PR). The sub-study included the collection of blood samples with assessment of 10 inflammatory markers prior to EBV treatment and 6 months after EBV or EBV+PR treatment.

Results: In 66 patients, 6 months after treatment a pro-inflammatory cytokine profile was observed, with an increase in all pro-inflammatory markers and a decrease in the anti-inflammatory cytokine interleukin-10. The changes in plasma cytokine profile were not associated with changes in clinical outcomes such as lung function or exercise capacity.

Discussion: In conclusion, our study demonstrated an elevation in systemic pro-inflammatory cytokine levels following successful EBV treatment, which was not associated with adverse clinical outcomes. It would be interesting to further explore whether this increase is attributed to a foreign body response or if other factors contribute to this phenomenon.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J.E. Hartman, M.C. van der Molen, M.R. Jonker, R. Posthuma and S.D. Pouwels have nothing to disclose. Conflict of interest: L.E.G.W. Vanfleteren reports to have received a research grant for this work from the Dutch Lung Foundation, grants or contracts from The Family Kamprad Foundation (20190024), the Swedish government and country council ALF grant (ALFGBG-824371), The Swedish Heart and Lung Foundation (20200150), Svensk Lungmedicinsk Förening (all paid to institution), and payment or honoraria for lectures, presentation, speakers’ bureaus, manuscript writing or educational events from GSK, Astrazeneca, Boehringer, Novartis, Chiesi, Resmed, Pulmonx and Grifols (paid personally). Conflict of interest: D-J. Slebos reports to have received grants or contracts from Pulmonx Corp USA, Nuvaira USA, PulmAir USA, Apreo USA and FreeFlowmedical (clinical trial expenses); consulting fees from Nuvaira USA, MoreAir USA, Apreo USA and PulmonX USA (all paid to institution); payment or honoraria for lectures, presentation, speakers’ bureaus, manuscript writing or educational events from PulmonX USA and Nuvaira USA (paid to institution); and support for attending meetings and/or travel from PulmonX USA.

Figures

FIGURE 1
FIGURE 1
Plasma cytokine levels at baseline and 6-month follow-up (FU). Whiskers indicate the median and interquartile ranges. Differences between baseline and 6-month follow-up were tested with a Wilcoxon signed rank test. *: p<0.05. IL-6: interleukin-6; CXCL8: interleukin-8; IL-10: interleukin-10; TNF-α: tumour necrosis factor-α; IFN-γ: interferon gamma; CCL-18: chemokine ligand 18; SP-D: surfactant protein D; sRAGE: soluble receptor for advanced glycation endproducts; hsCRP: high-sensitivity C-reactive protein.
See this image and copyright information in PMC

References

    1. Hartman JE, Vanfleteren LEGW, van Rikxoort EM,et al. Endobronchial valves for severe emphysema. Eur Respir Rev 2019; 28: 180121. doi: 10.1183/16000617.0121-2018 - DOI - PMC - PubMed
    1. Van Der Molen MC, Hartman, JE, Vanfleteren LEGW,et al. Reduction of lung hyperinflation improves cardiac preload, contractility, and output in emphysema: a prospective cardiac magnetic resonance study in patients who received endobronchial valves. Am J Respir Crit Care Med 2022; 206: 704–711. doi: 10.1164/rccm.202201-0214OC - DOI - PubMed
    1. Wienker J, Darwiche K, Rüsche N,et al. Body composition impacts outcome of bronchoscopic lung volume reduction in patients with severe emphysema: a fully automated CT-based analysis. Sci Rep 2024; 14: 8718. doi: 10.1038/s41598-024-58628-0 - DOI - PMC - PubMed
    1. Sanders KJC, Klooster K, Vanfleteren LEGW,et al. CT-derived muscle remodelling after bronchoscopic lung volume reduction in advanced emphysema. Thorax 2019; 74: 206–207. doi: 10.1136/thoraxjnl-2018-211931 - DOI - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2024 report. https://goldcopd.org/2024-gold-report/

LinkOut - more resources